(0.70%) 5 117.75 points
(0.15%) 38 347 points
(0.94%) 17 733 points
(0.41%) $83.91
(-3.30%) $1.584
(0.76%) $2 360.30
(1.25%) $27.70
(0.46%) $924.70
(-0.03%) $0.931
(0.31%) $10.99
(-0.04%) $0.799
(-0.22%) $91.96
Live Chart Being Loaded With Signals
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials...
Stats | |
---|---|
Today's Volume | 5.76M |
Average Volume | 3.01M |
Market Cap | 15.13B |
EPS | HKD0 ( 2023-08-10 ) |
Last Dividend | HKD0.140 ( 2023-06-09 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 8.00 |
ATR14 | HKD0.00300 (0.07%) |
Volume Correlation
China Grand Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
China Grand Correlation - Currency/Commodity
China Grand Financials
Annual | 2023 |
Revenue: | HKD10.53B |
Gross Profit: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2023 |
Revenue: | HKD10.53B |
Gross Profit: | HKD6.52B (61.96 %) |
EPS: | HKD0.540 |
FY | 2022 |
Revenue: | HKD9.56B |
Gross Profit: | HKD5.95B (62.24 %) |
EPS: | HKD0.590 |
FY | 2021 |
Revenue: | HKD8.60B |
Gross Profit: | HKD5.25B (61.03 %) |
EPS: | HKD0.677 |
Financial Reports:
No articles found.
China Grand Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.140 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0860 | 2019-06-12 |
Last Dividend | HKD0.140 | 2023-06-09 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | HKD0.542 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.09 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.50 | |
Div. Directional Score | 8.47 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
6601.HK | Ex Dividend Knight | 2023-09-13 | Annually | 0 | 0.00% | |
1897.HK | Ex Dividend Knight | 2023-07-05 | Semi-Annually | 0 | 0.00% | |
0921.HK | Ex Dividend Junior | 2023-07-10 | Sporadic | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
2869.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1469.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
0546.HK | Ex Dividend Knight | 2023-09-18 | Semi-Annually | 0 | 0.00% | |
6993.HK | Ex Dividend Junior | 2023-06-20 | Annually | 0 | 0.00% | |
1997.HK | Ex Dividend Junior | 2023-08-25 | Semi-Annually | 0 | 0.00% | |
1070.HK | Ex Dividend Junior | 2023-07-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.179 | 1.500 | 6.43 | 9.64 | [0 - 0.5] |
returnOnAssetsTTM | 0.0835 | 1.200 | 7.22 | 8.66 | [0 - 0.3] |
returnOnEquityTTM | 0.127 | 1.500 | 9.70 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.264 | -1.000 | 7.36 | -7.36 | [0 - 1] |
currentRatioTTM | 1.224 | 0.800 | 8.88 | 7.10 | [1 - 3] |
quickRatioTTM | 0.982 | 0.800 | 8.93 | 7.14 | [0.8 - 2.5] |
cashRatioTTM | 0.239 | 1.500 | 9.78 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.148 | -1.500 | 7.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 13.26 | 1.000 | 6.20 | 6.20 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.181 | 2.00 | 9.94 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.116 | 2.00 | 9.94 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.221 | -1.500 | 9.12 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.620 | 1.000 | 3.01 | 3.01 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.258 | 1.000 | 6.83 | 6.83 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0542 | -0.0542 | [0.2 - 2] |
assetTurnoverTTM | 0.468 | 0.800 | -0.216 | -0.172 | [0.5 - 2] |
Total Score | 11.45 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.00 | 1.000 | 9.29 | 0 | [1 - 100] |
returnOnEquityTTM | 0.127 | 2.50 | 9.81 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.116 | 2.00 | 9.96 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.26 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.181 | 2.00 | 9.94 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.264 | 1.500 | 7.36 | -7.36 | [0 - 1] |
pegRatioTTM | 0.165 | 1.500 | -2.23 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0604 | 1.000 | -0.990 | 0 | [0.1 - 0.5] |
Total Score | 5.50 |
China Grand
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers pharmaceutical preparations, including cerebro-cardiovascular emergency medicines; respiratory, ophthalmic, anti-infection, and ENT medicines; oncology medicines; and rare disease medicines. It also provides medical devices, such as vascular interventional medical devices comprising paclitaxel releasing coronary balloon dilatation catheters and paclitaxel releasing hemodialysis shunt balloon dilatation catheters; and ophthalmology related devices. In addition, the company offers biotechnology and health products, such as Taurine, amino acid products, steroid products, and bio-pesticides and agricultural antibiotics; and specialized pharmaceutical raw materials and other products, including metronidazole, chloramphenicol, epinephrine, dimethyl sulfate, nitromethane, etc. Further, the company offers agrochemicals, fine chemicals, and chemical medicines; ophthalmic gel and eye drops; steroid hormones active pharmaceutical ingredients and related intermediates; bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. Grand Pharmaceutical Group Limited has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited and changed its name to Grand Pharmaceutical Group Limited in November 2021. Grand Pharmaceutical Group Limited was incorporated in 1995 and is based in Central, Hong Kong.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators